Sionna Therapeutics reported that its Phase 2 cystic fibrosis add-on pill, SION-719, failed to show benefit when added to Vertex’s Trikafta, prompting the biotech to stop advancing the program and preserve capital. The decision removes a would-be challenger to Vertex’s CF franchise. In the trial, SION-719 was tested with Trikafta against Trikafta alone using sweat chloride as the key pharmacodynamic readout. Sionna reported the study did not achieve a statistically significant, placebo-adjusted change, which management said falls short of the differentiation level it expected. The response from markets was immediate, with Sionna’s stock plunging sharply after the top-line results. Vertex shares rose in parallel, underlining how tightly CF investors track incremental efficacy against Trikafta-based regimens.